|
시장보고서
상품코드
1747308
털세포 백혈병 시장 : 치료 유형별, 투여 경로별, 연령층별, 성별, 최종사용자별, 유통 채널별, 지역별Hairy Cell Leukemia Market, By Therapy Type, By Route of Administration, By Age Group, By Gender, By End User, By Distribution Channel, By Region |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 털세포 백혈병 시장은 2025년에는 1억 4,280만 달러, 2032년에는 2억 2,330만 달러에 이를 것으로 예측되며, 2025-2032년 CAGR 6.6%를 보일 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 1억 4,280만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간(2025-2032년) CAGR | 6.60% | 2032년 가치 예측 | 2억 2,330만 달러 |
세계 털세포백혈병 시장은 최근 유병률 증가, 진단 기술의 발전, 혁신적인 치료 옵션의 개발로 인해 최근 몇 년간 괄목할 만한 성장세를 보이고 있습니다. 털세포백혈병은 백혈구의 일종인 B림프구를 침범하는 희귀하고 만성적이며 천천히 성장하는 혈액암입니다. 이 질환은 골수, 혈액, 비장에 비정상적인 털세포가 존재하는 것이 특징이며, 피로, 잦은 감염, 비장 비대 등의 증상을 유발합니다. 이 질환에 대한 인식이 높아지고 효과적인 치료 옵션이 제공됨에 따라 세계 털세포백혈병 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예측됩니다.
시장 역학:
세계 털세포백혈병 시장은 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회 등 여러 요인의 영향을 받습니다. 시장의 주요 촉진요인 중 하나는 유전적 소인, 환경적 요인, 고령화 등의 요인에 기인하는 세계 털세포백혈병 유병률 증가입니다. 또한, 유세포 분석 및 면역 조직화학과 같은 진단 기술의 발전으로 질병의 검출 및 진단이 개선되어 시장 성장을 더욱 촉진하고 있습니다. 그러나 높은 치료 비용, 신흥국 시장에서의 낮은 질환 인지도, 화학요법 및 분자 표적 치료의 부작용 등의 요인으로 인해 시장 성장이 제한될 수 있습니다. 그러나 이러한 어려움에도 불구하고, 새로운 표적치료제 개발, 제약기업과 연구기관의 공동연구 증가, 신흥국가의 헬스케어 인프라 확충 등 시장에는 큰 성장 기회가 존재하고 있습니다. 또한, 개인 맞춤형 의료에 대한 관심이 높아지고 유전자 염기서열 분석, 분자 프로파일링과 같은 첨단 기술의 도입으로 향후 몇 년 동안 시장 성장의 새로운 길이 열릴 것으로 예측됩니다.
본 조사의 주요 특징
- 세계의 털세포 백혈병 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032) 시장 규모(USD Mn)와 연평균 성장률(CAGR%)을 조사하여 전해드립니다.
- 다양한 부문에 걸친 잠재적 수익 창출 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 털세포백혈병 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 털세포 백혈병 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 털세포백혈병 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
- 업계 동향
제4장 세계의 털세포 백혈병 시장, 치료 유형별, 2020년-2032년
- 화학요법
- Cladribine
- Pentostatin
- Targeted Therapy
- Ibrutinib
- Vemurafenib
- Moxetumomab Pasudotox
- Immunotherapy
- Monoclonal Antibodies
- Interferon Alpha
- 기타 병용요법(예 : Cladribine + Rituximab)
제5장 세계의 털세포 백혈병 시장, 투여 경로별, 2020년-2032년
- 경구
- 비경구
제6장 세계의 털세포 백혈병 시장, 연령 그룹별, 2020년-2032년
- 소아
- 성인
- 고령자
제7장 세계의 털세포 백혈병 시장, 성별, 2020년-2032년
- 남성
- 여성
제8장 세계의 털세포 백혈병 시장, 최종사용자별, 2020년-2032년
- 병원
- 종양학 클리닉
- 암 연구기관
- 외래 진료 센터
- 진단실험실
제9장 세계의 털세포 백혈병 시장, 유통 채널별, 2020년-2032년
- 소매 약국
- 병원 약국
- 온라인 약국
제10장 세계의 털세포 백혈병 시장, 지역별, 2020년-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제11장 경쟁 구도
- Novartis
- Roche
- Bristol-Myers Squibb
- Merck & Co.
- Amgen
- Gilead Sciences
- AbbVie
- Celgene
- Teva Pharmaceutical Industries
- Takeda Pharmaceutical Company
- Janssen Pharmaceuticals
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Bayer AG
제12장 애널리스트 추천 사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제13장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사에 대해
Global Hairy Cell Leukemia Market is estimated to be valued at USD 142.8 Mn in 2025 and is expected to reach USD 223.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 142.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.60% | 2032 Value Projection: | USD 223.3 Mn |
The global hairy cell leukemia market has witnessed significant growth in recent years, driven by increasing incidence rates, advancements in diagnostic techniques, and the development of innovative treatment options. Hairy cell leukemia is a rare, chronic, and slow-growing type of blood cancer that affects B lymphocytes, a type of white blood cell. The disease is characterized by the presence of abnormal hairy cells in the bone marrow, blood, and spleen, leading to symptoms such as fatigue, frequent infections, and an enlarged spleen. With the rising awareness about the disease and the availability of effective treatment options, the global hairy cell leukemia market is expected to experience substantial growth during the forecast period.
Market Dynamics:
The global hairy cell leukemia market is influenced by several factors, including drivers, restraints, and opportunities. One of the key drivers of the market is the increasing incidence of hairy cell leukemia worldwide, which can be attributed to factors such as genetic predisposition, environmental factors, and an aging population. Additionally, advancements in diagnostic techniques, such as flow cytometry and immunohistochemistry, have led to improved detection and diagnosis of the disease, further driving market growth. However, the market growth may be restrained by factors such as the high cost of treatment, limited awareness about the disease in developing regions, and the side effects associated with chemotherapy and targeted therapy. Despite these challenges, the market presents significant opportunities for growth, including the development of novel targeted therapies, increasing collaborations between pharmaceutical companies and research institutions, and the expansion of healthcare infrastructure in emerging economies. Moreover, the growing focus on personalized medicine and the adoption of advanced technologies, such as gene sequencing and molecular profiling, are expected to create new avenues for market growth in the coming years.
Key Features of the Study:
- This report provides in-depth analysis of the global hairy cell leukemia market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hairy cell leukemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis, Roche, Bristol-Myers Squibb, Merck & Co., Amgen, Gilead Sciences, AbbVie, Celgene, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company, Janssen Pharmaceuticals, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hairy cell leukemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hairy cell leukemia market
Market Segmentation
- Therapy Type Insights (Revenue, USD Mn, 2020 - 2032)
- Chemotherapy
- Cladribine
- Pentostatin
- Targeted Therapy
- Ibrutinib
- Vemurafenib
- Moxetumomab Pasudotox
- Immunotherapy
- Monoclonal Antibodies
- Interferon Alpha
- Others Combination Regimens (e.g., Cladribine + Rituximab)
- Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
- Oral
- Parenteral
- Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Mn, 2020 - 2032)
- Male
- Female
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals
- Oncology Clinics
- Cancer Research Organizations
- Ambulatory Care Centers
- Diagnostic Laboratories
- Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis
- Roche
- Bristol-Myers Squibb
- Merck & Co.
- Amgen
- Gilead Sciences
- AbbVie
- Celgene
- Teva Pharmaceutical Industries
- Takeda Pharmaceutical Company
- Janssen Pharmaceuticals
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Hairy Cell Leukemia Market, By Therapy Type
- Global Hairy Cell Leukemia Market, By Route of Administration
- Global Hairy Cell Leukemia Market, By Age Group
- Global Hairy Cell Leukemia Market, By Gender
- Global Hairy Cell Leukemia Market, By End User
- Global Hairy Cell Leukemia Market, By Distribution Channel
- Global Hairy Cell Leukemia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Hairy Cell Leukemia Market, By Therapy Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Cladribine
- Pentostatin
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Ibrutinib
- Vemurafenib
- Moxetumomab Pasudotox
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Monoclonal Antibodies
- Interferon Alpha
- Others Combination Regimens (e.g., Cladribine + Rituximab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Hairy Cell Leukemia Market, By Route of Administration, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Hairy Cell Leukemia Market, By Age Group, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Hairy Cell Leukemia Market, By Gender, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Hairy Cell Leukemia Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Oncology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Cancer Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Ambulatory Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
9. Global Hairy Cell Leukemia Market, By Distribution Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
10. Global Hairy Cell Leukemia Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
샘플 요청 목록